Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. (2022)

First Author: Sokhela S
Attributed to:  New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkac266

PubMed Identifier: 35953881

Publication URI: http://europepmc.org/abstract/MED/35953881

Type: Journal Article/Review

Volume: 77

Parent Publication: The Journal of antimicrobial chemotherapy

Issue: 10

ISSN: 0305-7453